Adrian Rawcliffe has been promoted to the position of chief executive of Adaptimmune Therapeutics Plc, succeeding co-founder James Noble who will retire on 1 September. Mr Rawcliffe has been chief financial officer since 2015 when he joined Adaptimmune from GlaxoSmithKline Plc. At GSK he was head of finance for the company’s North American pharmaceuticals business and before that, a managing partner of SR One Ltd, GSK’s venture capital business. Mr Rawcliffe holds a Bachelor of Science degree in natural sciences from the University of Durham and qualified as a chartered accountant with PricewaterhouseCoopers, both in the UK.
Adaptimmune announced the appointment on 27 June 2019.
Copyright 2019 Evernow Publishing Ltd.